» Articles » PMID: 24404135

Role of SOX2 in the Etiology of Embryonal Carcinoma, Based on Analysis of the NCCIT and NT2 Cell Lines

Overview
Journal PLoS One
Date 2014 Jan 10
PMID 24404135
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The transcription factor SOX2, associated with amongst others OCT3/4, is essential for maintenance of pluripotency and self-renewal of embryonic stem cells. SOX2 is highly expressed in embryonal carcinoma (EC), the stem cell component of malignant nonseminomatous germ cell tumors, referred to as germ cell cancer (GCC). In fact, OCT3/4 together with SOX2 is an informative diagnostic tool for EC in a clinical setting. Several studies support the hypothesis that SOX2 is a relevant oncogenic factor in various cancers and recently, SOX2 has been suggested as a putative therapeutic target for early stage EC. We demonstrate the presence of genomic amplification of SOX2 in an EC cell line, NCCIT, using array comparative genome hybridization and fluorescence in situ hybridization. Down-regulation of SOX2 by targeted siRNA provokes NCCIT cells towards apoptosis, while inhibition of OCT3/4 expression induced differentiation, with retained SOX2 levels. Mice pluripotent xenografts from NCCIT (N-NCCIT and N2-NCCIT) show a consistent SOX2 expression, in spite of loss of the expression of OCT3/4, and differentiation, with retained presence of genomic amplification. No SOX2 amplification has been identified in primary pure and mixed EC in vivo patient samples so far. The data presented in this study are based on a single EC cell line with a SOX2 amplification, with NT2 as control EC cell line, showing no profound induction of apoptosis upon SOX2 downregulation. The findings are of relevance to identify mechanisms involved in the pathogenesis of EC tumors, and support the model of SOX2-oncogene dependency of EC, which however, does not exclude induction of differentiation. This finding is likely related to the presence of wild type p53 in GCC, resulting in expression of downstream target genes, amongst others miR-34a, miR-145 and SOX2, associated to the unique sensitivity of GCC to DNA damaging agents.

Citing Articles

An integrated approach for the accurate detection of HERV-K HML-2 transcription and protein synthesis.

Gleason C, Terry S, Hernandez M, Jacob S, Fenyo D, Johnson J Nucleic Acids Res. 2025; 53(2).

PMID: 39831303 PMC: 11744191. DOI: 10.1093/nar/gkaf011.


The Subtype Identity of Testicular Cancer Cells Determines Their Immunostimulatory Activity in a Coculture Model.

Gayer F, Henkel M, Luft J, Reichardt S, Fichtner A, Legler T Cancers (Basel). 2023; 15(9).

PMID: 37174085 PMC: 10177190. DOI: 10.3390/cancers15092619.


Epigenetic Regulation of Driver Genes in Testicular Tumorigenesis.

von Eyben F, Kristiansen K, Kapp D, Hu R, Preda O, Nogales F Int J Mol Sci. 2023; 24(4).

PMID: 36835562 PMC: 9966837. DOI: 10.3390/ijms24044148.


Role of MicroRNAs in Neuroendocrine Prostate Cancer.

Sreekumar A, Saini S Noncoding RNA. 2022; 8(2).

PMID: 35447888 PMC: 9029336. DOI: 10.3390/ncrna8020025.


Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry.

Fichtner A, Bohnenberger H, Elakad O, Richter A, Lenz C, Oing C World J Urol. 2022; 40(2):373-383.

PMID: 35084545 PMC: 8921118. DOI: 10.1007/s00345-022-03936-1.


References
1.
Bae K, Su Z, Frye C, McClellan S, Allan R, Andrejewski J . Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol. 2010; 183(5):2045-53. PMC: 4451595. DOI: 10.1016/j.juro.2009.12.092. View

2.
Yang S, Lin G, Deng L, Lu G . Tumourigenic characteristics of embryonal carcinoma cells as a model for studying tumour progression of human embryonic stem cells. Cell Prolif. 2012; 45(4):299-310. PMC: 6496526. DOI: 10.1111/j.1365-2184.2012.00827.x. View

3.
Damjanov I, Horvat B, Gibas Z . Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT. Lab Invest. 1993; 68(2):220-32. View

4.
Kilkenny C, Browne W, Cuthill I, Emerson M, Altman D . Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010; 8(6):e1000412. PMC: 2893951. DOI: 10.1371/journal.pbio.1000412. View

5.
Lu Y, Futtner C, Rock J, Xu X, Whitworth W, Hogan B . Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One. 2010; 5(6):e11022. PMC: 2883553. DOI: 10.1371/journal.pone.0011022. View